Background: Ketamine and gabapentin have been shown to prevent the delayed hyperalgesia induced by short-term use of systemic opioids. The mechanism of this action is believed to be likely at the spinal level, through an antagonism of the N-methyl-D-aspartate receptors for ketamine, and through a specific binding site for gabapentin. In this study, we sought to determine the nature of the interaction of these 2 mechanistically distinct antihyperalgesic drugs in a model of opioid-induced hyperalgesia in rats. The median effective antihyperalgesic doses of each drug and of their combination were first defined, to assess the nature of the interaction using an isobolographic analysis.

Methods: Long-lasting hyperalgesia was induced in male Sprague Dawley rats with subcutaneous fentanyl (4 injections, 60 μg/kg per injection at 15-minute intervals) resulting in a total dose of 240 μg/kg. Subcutaneous ketamine, or intraperitoneal gabapentin, or their combination was administered 30 minutes before the first subcutaneous fentanyl injection. Sensitivity to nociceptive stimuli (von Frey filaments) was assessed on the day of the experiment and on the day after injections. The dose of ketamine and gabapentin received by a particular animal was determined by the response of the previous animal of the same group, using an up-and-down technique. Initial doses were 10 mg/kg and 300 mg/kg, with dose adjustment intervals of 1 mg/kg and 30 mg/kg, in the ketamine and gabapentin groups, respectively. The initial doses of ketamine and gabapentin were 5 mg/kg and 150 mg/kg, respectively, in the ketamine-gabapentin group, with the same dose adjustment intervals. Antihyperalgesic efficacy was defined as complete prevention of hyperalgesia on the day after drug injections.

Results: The median effective antihyperalgesic doses (median value and 95% confidence interval) of ketamine and gabapentin were 12.4 mg/kg (11.7-13.1 mg/kg) and 296.3 mg/kg (283.5-309.1 mg/kg), respectively. The median effective antihyperalgesic dose of the combination was 4.3 mg/kg (3.7-4.6 mg/kg) for ketamine and 123.9 mg/kg (111.1-136.7 mg/kg) for gabapentin.

Conclusion: The isobolographic analysis demonstrated that the combination of the 2 drugs produces effective antihyperalgesia with a supraadditive (synergistic) action.

Download full-text PDF

Source
http://dx.doi.org/10.1213/ANE.0b013e3182222b59DOI Listing

Publication Analysis

Top Keywords

ketamine gabapentin
24
median effective
16
mg/kg
14
effective antihyperalgesic
12
ketamine
9
dose ketamine
8
gabapentin
8
opioid-induced hyperalgesia
8
hyperalgesia rats
8
isobolographic analysis
8

Similar Publications

Complex regional pain syndrome (CRPS) is a chronic neuropathic pain disorder often following trauma, associated with severe pain and autonomic disturbances in the affected limbs. Managing CRPS is challenging due to the lack of FDA-approved medications, often requiring off-label treatments. Traditional options like nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids show limited efficacy, while adjunctive treatments such as gabapentin, antidepressants, and bisphosphonates are increasingly favored.

View Article and Find Full Text PDF
Article Synopsis
  • - The study reviewed the effectiveness of topical medications for diabetic neuropathic pain (DNP) and compared them with oral pain relief options.
  • - The most promising topical treatments identified were 8% Capsaicin patches and 5% Lidocaine patches, along with evidence supporting topical clonidine, gabapentin, and amitriptyline.
  • - Topical medications could be viable alternatives to oral medications for DNP, and further research is needed on combining different topical treatments for better effectiveness.
View Article and Find Full Text PDF

Introduction: Evidence-based principles in enhanced recovery programs (ERPs) demonstrate substantial improvement in patient outcomes. Determining which latent variables predict composite outcomes could refine ERP pharmacotherapy recommendations.

Methods: Using R, pharmacotherapy data were modeled from an existing dataset of adult elective colorectal surgery patients.

View Article and Find Full Text PDF

Efficacy of nonopioid analgesics and adjuvants in multimodal analgesia for reducing postoperative opioid consumption and complications in obesity: a systematic review and network meta-analysis.

Br J Anaesth

December 2024

Department of Medicine - DIMED, Section of Anaesthesiology and Intensive Care, University of Padova, Padova, Italy; Institute of Anaesthesia and Intensive Care, Padua University Hospital, Padova, Italy.

Article Synopsis
  • Managing postoperative pain for patients with obesity is complicated, and this study explores the effectiveness of various nonopioid intravenous analgesics and adjuvants in reducing opioid use and recovery complications after surgery.
  • A systematic review of 37 randomized controlled trials found that medications like dexmedetomidine, ketamine, lidocaine, and gabapentin significantly decreased opioid consumption and postoperative issues such as nausea and vomiting in these patients.
  • The findings suggest that these nonopioid analgesics are vital in improving postoperative care, ultimately leading to better outcomes for obese patients undergoing surgery.
View Article and Find Full Text PDF

Objective: To describe analgesic-related deaths in France and report trends over a 10-year period.

Study Design: The DTA ("Décès Toxiques par Antalgiques") register is a French database of analgesic-related deaths among people without a history of drug abuse, reported by forensic toxicology experts.

Methods: We included analgesic-related deaths occurring from January 2013 to December 2022 in France.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!